Prevalence, Issues, and Clinical Challenges of Addressing Overweight/Obesity Among Persons with Hemophilia

This activity has expired.
Release Date: April 24, 2017
Expiration Date: April 24, 2018
Estimated Time to Complete Activity: 60 minutes
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologists/oncologists, pediatricians, registered nurses, advanced practice registered nurses and hemophilia treatment center staff, registered with the Blood CME Center, who are involved in the comprehensive care of people with hemophilia (PWH).

Statement of Need/Program Overview

Overweight and obesity has an adverse effect on health care cost, chronic complications, and joint disease in PWH. Although many health care providers recognize that overweight/obese patients are at risk, there are gaps in the efforts employed to reduce the prevalence and improve weight management practices and individual comprehensive care of these patients.

Educational Objectives
After participating in this activity, participants should be able to:

  • Evaluate the CDC study and other relevant data on the prevalence of overweight/obesity in PWH
  • Assess the effect of overweight/obesity on bleeding frequency and replacement factor concentrate usage
  • Review how to calculate and interpret BMI among PWH in order to determine risk and develop appropriate management strategies
  • Implement appropriate prevention and intervention strategies for screening, treating, counseling, and appropriate referral of PWH who are overweight/obese


Presenting Faculty

Suvankar Majumdar, MD
Suvankar Majumdar, MD
Associate Professor
Pediatric Hematology Oncology
University of Mississippi Medical Center
Jackson, Mississippi

Michael Recht, MD, PhD
Michael Recht, MD, PhD
Professor of Pediatrics and Medicine
Director, The Hemophilia Center
Oregon Health & Science University
Portland, Oregon

Megan Ullman, MA, MPH
Megan Ullman, MA, MPH
Senior Research Associate
Gulf States Hemophilia and Thrombophilia Center
University of Texas Health Science Center at Houston
Houston, Texas

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Designated for 0.3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Method of Participation
During the period of April 24, 2017 through April 24, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form

A statement of credit will be issued automatically upon successfully completing the post-activity survey with a score of 75% or better and submitting the activity evaluation.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Suvankar Majumdar, MD Has no real or apparent conflicts of interest to report.
Michael M. Recht, MD, PhD Research support: Biogen, Genentech, NovoNordisk, Shire
Scientific advisory boards: Biogen, CSL Behring, Genentech, Kedrion, NovoNordisk, Pfizer, Shire
Non-profit boards: Chair of Board, American Thrombosis and Hemostasis Network
Patents: DA15 (an interferon-induced protein)
Megan Ullman, MA, MPH Has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP

Have no real or apparent conflicts of interest to report.

ECM: Patrick J. Crowley, MBA, Partner/CEO; Jodi Andrews, BS, Partner/COO; Jo-Ann Angelucci, BA, Program Director; Larry Rosenberg, PhD, Medical Writer Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM and Educational Concepts in Medicine do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by an educaitonal grant from Novo Nordisk

Fee Information
There is no fee for this educational activity.